Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
APLM
Apollomics, Inc.
The company is a biotechnology oncology-focused firm actively developing cancer therapies (vebreltinib and apolecylin) with multiple clinical programs.
|
$22.63M |
N/A
|
|
XCUR
Exicure, Inc.
GPCR USA's lead asset GPC-100.00 is an oncology biotech product in development, representing the core biotech asset.
|
$22.55M |
$3.61
+1.12%
|
|
IOBT
IO Biotech, Inc.
IO Biotech's lead candidate is a therapeutic cancer vaccine (off-the-shelf cancer vaccines) and IO102-IO103 is built on a vaccine platform.
|
$21.86M |
$0.33
-1.08%
|
|
AKTX
Akari Therapeutics, Plc
Core product category: antibody-drug conjugates (ADC) platform and lead AKTX-101 using PH1 payload targeting Trop2.
|
$20.35M |
$0.28
-31.68%
|
|
VYNE
VYNE Therapeutics Inc.
Company's core focus is immunology therapeutics powered by a BET inhibitor platform.
|
$19.59M |
$0.59
-0.66%
|
|
FBLG
FibroBiologics, Inc. Common Stock
Core business is fibroblast-based cell therapies (CYWC628, CYMS101, CybroCell) in regenerative medicine; directly matches Biotech - Cell Therapy.
|
$19.33M |
$0.42
+12.11%
|
|
CVM
CEL-SCI Corporation
Direct product category for CEL-SCI's lead immunotherapy for cancer (Multikine) under oncology biotech.
|
$19.30M |
$6.07
-4.64%
|
|
MRKR
Marker Therapeutics, Inc.
Marker Therapeutics develops MAR-T cell therapies, a cell-based immunotherapy platform targeting cancer.
|
$19.15M |
$1.48
-6.33%
|
|
TLPH
Talphera, Inc.
Talphera is developing ready-to-use pre-filled syringe formulations (e.g., Fedsyra) for nafamostat-based therapies.
|
$18.71M |
$0.91
-2.03%
|
|
PMN
ProMIS Neurosciences, Inc.
PMN310 is a monoclonal antibody therapeutic targeting toxic amyloid-beta oligomers for Alzheimer's disease.
|
$18.63M |
$8.62
-1.54%
|
|
OTLC
Oncotelic Therapeutics, Inc.
OT-101 is an antisense oligonucleotide targeting TGFB2, fitting the Oligonucleotide Therapeutics category.
|
$17.30M |
$0.05
|
|
SER
Serina Therapeutics, Inc.
Direct proprietary POZ drug delivery platform enabling long-acting, subcutaneous drug release for CNS therapeutics.
|
$17.12M |
$1.60
-3.89%
|
|
NAII
Natural Alternatives International, Inc.
Direct contract manufacturing services for private-label vitamins, minerals, herbal and other health care products.
|
$17.11M |
$2.77
|
|
EVOK
Evoke Pharma, Inc.
Gimoti relies on a nasal drug-delivery platform/technology, making Drug Delivery Platforms a core investable theme for Evoke's product strategy.
|
$17.07M |
$10.98
+0.32%
|
|
CVKD
Cadrenal Therapeutics, Inc. Common Stock
Cadrenal's tecarfarin is described as a novel oral small-molecule therapeutic, directly aligning with the 'Oral Small Molecule Therapeutics' tag.
|
$16.99M |
$8.28
-0.24%
|
|
MDXH
MDxHealth S.A.
GPS test provides biomarker-based risk stratification that informs treatment decisions, aligning with Companion Diagnostics.
|
$16.93M |
$3.31
-3.07%
|
|
APUS
Apimeds Pharmaceuticals US, Inc
APUS's lead product Apitox is a bee venom-based immunology/anti-inflammatory therapy targeting OA pain and potential MS, fitting the Immunology Therapeutics category.
|
$16.73M |
$1.36
+2.26%
|
|
GNTA
Genenta Science S.p.A.
Genenta's lead program is a gene therapy platform.
|
$16.65M |
$0.91
-0.52%
|
|
ANEB
Anebulo Pharmaceuticals, Inc.
Anebulo's lead candidate selonabant is a small molecule therapeutic (initially oral) targeting cannabis-induced CNS effects; thus aligns with Oral Small Molecule Therapeutics.
|
$16.42M |
$0.37
-7.59%
|
|
PALI
Palisade Bio, Inc.
Lead asset PALI-2108 targets immunology/inflammatory diseases (IBD), aligning with Immunology Therapeutics.
|
$15.87M |
$1.64
-6.03%
|
|
JUNS
Jupiter Neurosciences, Inc.
Direct product category: orally administered small-molecule therapeutics based on a resveratrol platform (JOTROL).
|
$15.78M |
$0.41
-9.74%
|
|
LEXX
Lexaria Bioscience Corp.
Lexaria's DehydraTECH is a proprietary drug delivery platform that enhances API absorption and enables oral formulations.
|
$15.76M |
$0.68
-4.09%
|
|
CTXR
Citius Pharmaceuticals, Inc.
LYMPHIR is a targeted oncology immunotherapy for CTCL, representing a core commercial product.
|
$15.36M |
$0.73
-3.71%
|
|
ALLR
Allarity Therapeutics, Inc.
Allarity is a clinical-stage biotech focused on oncology therapies (stenoparib) and cancer drug development.
|
$15.35M |
$1.00
-4.76%
|
|
APLT
Applied Therapeutics, Inc.
Applied Therapeutics is a biotech focused on rare diseases, with lead programs in rare metabolic/neurologic conditions (e.g., govorestat for CMT-SORD) and out-licensing efforts in rare disease assets.
|
$14.83M |
$0.11
+4.37%
|
|
ADAP
Adaptimmune Therapeutics plc
Adaptimmune develops engineered T-cell therapies (cell therapy) for cancer, including TECELRA and lete-cel.
|
$14.58M |
$0.06
+2.91%
|
|
INTS
Intensity Therapeutics, Inc.
Company develops oncology-focused therapeutics (INT230-6.00) and operates in Biotech - Oncology.
|
$14.49M |
$7.54
-2.08%
|
|
TPST
Tempest Therapeutics, Inc.
Tempest is a clinical-stage biotechnology company focused on oncology with lead and follow-on small molecule cancer programs.
|
$13.81M |
$3.15
-0.16%
|
|
PVCT
Provectus Biopharmaceuticals, Inc.
VisiRose EyeCo focuses on ophthalmic topical RBS (PV-305) for infectious keratitis, an ophthalmic drug product.
|
$13.60M |
$0.06
|
|
HOTH
Hoth Therapeutics, Inc.
HT-001 (oncology supportive care) and HT-KIT/HT-ALZ pipelines place Hoth in oncology/biotech with a focused cancer therapy strategy.
|
$13.39M |
$1.00
-3.37%
|
|
BLRX
BioLineRx Ltd.
BioLineRx's lead oncology asset motixafortide (APHEXDA) places the company squarely in oncology with an approved stem cell mobilization therapy and ongoing cancer indications development.
|
$13.32M |
$2.81
|
|
KAPA
Kairos Pharma, Ltd.
Kairos Pharma is a clinical-stage biopharma focused on oncology therapies, including immunotherapies and cell therapies.
|
$13.06M |
$0.63
+0.19%
|
|
CRIS
Curis, Inc.
Curis's core business is oncology-focused biotech developing cancer therapies, anchored by emavusertib.
|
$12.87M |
$1.03
|
Showing page 21 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
